Literature DB >> 8814421

Immunoglobulin M in cerebrospinal fluid: reference values derived from 111 healthy individuals 18-88 years of age.

K Blennow1, I Skoog, A Wallin, C Wikkelsö, P Fredman.   

Abstract

The importance of immunoglobulin M (IgM) determination in cerebrospinal fluid (CSF) has increased parallel to the need for early diagnosis of infectious and inflammatory disorders of the central nervous system. Current reference values are based on analysis of CSF from 'reference groups' consisting of patients with psychiatric and/or neurological symptoms but without positive clinical findings. Therefore, accurate reference values for CSF IgM are of utmost importance. The present study presents reference values for IgM in CSF in a large sample (n = 111) of healthy individuals with an age span of 18-88 years. The upper reference limit, calculated as the 0.95 fractile, was 0.36 mg/l for CSF IgM, 0.40 for CSF/serum IgM ratio, and 0.045 for the IgM index. These parameters showed no significant difference between sexes nor any significant correlations with age. The correlations between CSF/serum albumin ratio and CSF/S IgM ratio were linear and statistically highly significant, suggesting that the IgM index values do not depend on the blood-CSF barrier function within the normal range of the CSF/serum albumin ratio.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814421     DOI: 10.1159/000117248

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  3 in total

1.  Pathognomonic cerebrospinal fluid findings in Bing-Neel syndrome.

Authors:  Henrik Zetterberg
Journal:  J Neurooncol       Date:  2011-01-09       Impact factor: 4.130

2.  Human African trypanosomiasis: a latex agglutination field test for quantifying IgM in cerebrospinal fluid.

Authors:  V Lejon; P Büscher; N H Sema; E Magnus; N Van Meirvenne
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

3.  A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.

Authors:  Andrew Eisen; Benjamin M Greenberg; James D Bowen; Douglas L Arnold; Anthony O Caggiano
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.